Blue Dress

The FDA has approved a groundbreaking Alzheimer’s drug, lecanemab, shown to modestly slow cognitive decline in early-stage patients. While hailed as a crucial step, experts caution about risks of brain swelling and bleeding, emphasizing it’s not a cure but a significant new treatment option.